Seattle Genetics licenses technology to GSK

12/21/2009 | Reuters

Seattle Genetics granted GlaxoSmithKline rights to use its antibody-drug conjugate technology. GSK will pay Seattle Genetics $12 million upfront and as much as $390 million in milestone fees if all ADC products created as a result of the deal reach the market.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA